An observational study in Breast Cancer Surgery, Locoregional Anaesthesia and Hypnosis, sponsored by Hôpital Fribourgeois. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Hôpital Fribourgeois · Observational
The goal of this observational study is to evaluate the feasibility of a standardized locoregional anesthesia protocol for patients undergoing breast cancer surgery under procedural sedation or adjunctive hypnosis.
The main questions it aims to answer are:
Participants will:
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 65 is below the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Hôpital Fribourgeois is the lead sponsor of 18 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adult patients scheduled for unilateral breast cancer surgery at HFR Fribourg during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a standardized locoregional anesthesia protocol consisting of predefined ultrasound-guided fascial plane blocks for breast cancer surgery, combined with either procedural sedation or adjunctive hypnosis, according to routine clinical practice at the study institution.
Successful completion of surgery without conversion to general anesthesia
Proportion of participants in whom surgery is completed under locoregional anesthesia without conversion to general anesthesia requiring airway instrumentation.
Time frame: Intraoperative period (from surgical incision to end of surgery)
Patient acceptance
Proportion of eligible patients accepting the proposed locoregional anesthesia pathway.
Time frame: Preoperative period (before surgery)
Adherence to the standardized protocol
Proportion of enrolled participants in whom the standardized protocol is applied as planned.
Time frame: Periprocedural
Anesthesia induction time
Time from participant arrival in the operating room to surgical incision.
Time frame: Periprocedural (before surgical incision)
Surgeon satisfaction
Surgeon satisfaction with operative conditions assessed using a 5-point Likert satisfaction scale, ranging from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction
Time frame: Intraoperative period (immediately after surgery)
Patient satisfaction
Patient satisfaction with anesthetic management assessed using a 5-point Likert satisfaction scale, ranging from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction.
Time frame: Perioperative period (before hospital discharge)
Perioperative complications
Incidence of complications related to locoregional anesthesia, sedation, hypnosis, or conversion to general anesthesia.
Time frame: Perioperative period (from anesthesia start to hospital discharge)
Reasons for conversion to general anesthesia
Description of reasons leading to conversion, when applicable.
Time frame: Intraoperative period
Plan to share: No
Start is estimated for Jan 2027; primary completion for Apr 2028, 15 months later.
Of 1,191 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 15 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Fribourgeois